SCHEMBL3602136

SCHEMBL3602136

Nc1nc(-c2ccccc2)nc2[nH]nc(Nc3ccccc3)c12

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 8/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PDE5A O76074 5/20 0.46
LMNA P02545 3/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
MAPT P10636 2/20 0.42
GFER P55789 1/20 0.42
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GSK3B P49841 1/20 0.40
TGFBR1 P36897 1/20 0.40
MAPK14 Q16539 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600310 0.91 ABCG2 (0.52) ABCG2MEN1KMT2APDE5ALMNA
SCHEMBL3409105 0.91 ABCG2 (0.52) ABCG2MEN1KMT2APDE5AGAA
SCHEMBL3413002 0.91 ABCG2 (0.54) ABCG2MEN1KMT2APDE5ALMNA
SCHEMBL3415833 0.91 MAPT (0.52) ABCG2MEN1KMT2ALMNAMAPT
SCHEMBL16139155 0.91 MAPT (0.47) ABCG2MEN1KMT2ALMNAMAPT
SCHEMBL19453194 0.89 ABL1 (0.46) ABCG2MEN1KMT2APDE5ALMNA
SCHEMBL14861915 0.89 ABCG2 (0.56) ABCG2MEN1KMT2ARAB9A
SCHEMBL16492396 0.88 ABCG2 (0.55) ABCG2PDE5AGAAMAPTKDM4E
SCHEMBL3408510 0.88 ABCG2 (0.56) ABCG2MEN1KMT2APDE5ALMNA
SCHEMBL3592180 0.88 MAPT (0.55) ABCG2MEN1KMT2ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2766367-B1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for the treatment of viral infections, in particular picornavirus infections SCANDION ONCOLOGY AS (DK) 2022-05-18 EP claimed
US-20180044341-A1 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES FOR USE AS BCRP INHIBITORS IN THERAPEUTIC TREATMENTS DRITTE PATENTPORTFOLIO BETEILIGUNGS-GESELLSCHAFT MBH & CO. KG (DE) 2018-02-15 US claimed
EP-3064207-B1 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments SCANDION ONCOLOGY AS (DK) 2017-12-20 EP claimed
US-9790225-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2017-10-17 US claimed
EP-3064207-A1 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG (DE) 2016-09-07 EP claimed
US-8962634-B2 4-amino-3-arylamino-6-arylpyrazolo[3,4-d) pyrimidine derivatives, methods for their preparation and their use as antiviral agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2015-02-24 US claimed
US-20140296259-A1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2014-10-02 US claimed
EP-2766367-B1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for the treatment of viral infections, in particular picornavirus infections SCANDION ONCOLOGY AS (DK) 2022-05-18 EP disclosed
EP-2766367-B1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for the treatment of viral infections, in particular picornavirus infections SCANDION ONCOLOGY AS (DK) 2022-05-18 EP disclosed
EP-2766367-B1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for the treatment of viral infections, in particular picornavirus infections SCANDION ONCOLOGY AS (DK) 2022-05-18 EP disclosed
US-10975079-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments SCANDION ONCOLOGY A/S (DK) 2021-04-13 US disclosed
US-10975079-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments SCANDION ONCOLOGY A/S (DK) 2021-04-13 US disclosed
US-10975079-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments SCANDION ONCOLOGY A/S (DK) 2021-04-13 US disclosed
US-20140296259-A1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2014-10-02 US disclosed
EP-2766367-A1 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS ANTIVIRAL ACTIVE SUBSTANCES Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG (DE) 2014-08-20 EP disclosed
CN-103946224-A 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d] pyrimidine derivatives, their manufacture and their use as antiviral active substances DRITTE PATENTPORTFOLIO BETEILI 2014-07-23 CN disclosed
WO-2013053942-A1 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D] PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS ANTIVIRAL ACTIVE SUBSTANCES DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2013-04-18 WO disclosed
WO-2013053942-A1 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D] PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS ANTIVIRAL ACTIVE SUBSTANCES DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2013-04-18 WO disclosed
US-20100010018-A1 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2010-01-14 US disclosed
US-20100010018-A1 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296259-A1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances POLL, RPP30, EIF2AK2 ABCG2 1780/4885MEN1 4757/4885KMT2A 3508/4885
US-20180044341-A1 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES FOR USE AS BCRP INHIBITORS IN THERAPEUTIC TREATMENTS ABCB1, ABCC1, MPHOSPH6 ABCG2 5/4885MEN1 4872/4885KMT2A 2807/4885
US-20100010018-A1 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents PNP, TYMP, EIF2AK2 ABCG2 136/4885MEN1 4838/4885KMT2A 3580/4885
US-10975079-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments ABCB1, ABCC1, MPHOSPH6 ABCG2 5/4885MEN1 4872/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.